RecruitingPhase 2NCT06530550

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Studying Lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator
Shuhua Yi, Doctor
Institute of Hematology & Blood Diseases Hospital, China
Intervention
PI3K inhibitor(drug)
Enrollment
51 enrolled
Eligibility
18 years · All sexes
Timeline
20242028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06530550 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma

← Back to all trials